features: Radiotherapy

177Lu-PSMA-617 approved for use in patients with PSMA+ mCRPC

As of the 23rd March 2022, the U.S. Food and Drug Administration (FDA) has approved 177Lu-PSMA-617 (a.k.a. Lu 177 Vipivotide…

Read More

Highlights from ESMO 2021

Check out our top picks from ESMO 2021!

Read More

Key updates from EAU 2021

VJOncology presents highlights from this year’sEuropean Association of Urology (EAU) Virtual Meeting 2021!

Read More

St Gallen 2021 Highlights

VJOncology are excited to present some key abstracts and trial updates announced at this year’s virtual St. Gallen Breast Cancer…

Read More

Accelerating the pace from bench to beside: the NIHR Oncology Translational Research Collaboration

In a nationwide effort to prioritize and accelerate translational research, a brand-new oncology research collaboration has been established by The…

Read More

New report – Radioligand therapy: realizing the potential of targeted cancer care

The Health Policy Partnership and an expert-led steering committee met at the European Parliament in Brussels on the 22nd of…

Read More

When radiation therapy causes heart disease

It has been known for almost a century that thoracic radiotherapy can cause damage to the heart.[2] However, the first…

Read More

Women treated for precursor of breast cancer can expect to live as long as other women

Women over 50 who have been treated for ductal carcinoma in situ (DCIS) are more likely to be alive ten…

Read More

Twice-daily radiation therapy cuts deaths from head and neck cancer

Treating head and neck cancer patients with a twice-daily radiation therapy combined with chemotherapy could save more lives, according to…

Read More
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals